Logo image of TGTX

TG THERAPEUTICS INC (TGTX) Stock Fundamental Analysis

NASDAQ:TGTX - Nasdaq - US88322Q1085 - Common Stock - Currency: USD

45.37  -0.14 (-0.31%)

After market: 45.1 -0.27 (-0.6%)

Fundamental Rating

5

TGTX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 566 industry peers in the Biotechnology industry. TGTX has only an average score on both its financial health and profitability. TGTX is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year TGTX was profitable.
TGTX had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: TGTX reported negative net income in multiple years.
In the past 5 years TGTX always reported negative operating cash flow.
TGTX Yearly Net Income VS EBIT VS OCF VS FCFTGTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

The Return On Assets of TGTX (4.05%) is better than 93.46% of its industry peers.
TGTX's Return On Equity of 10.52% is amongst the best of the industry. TGTX outperforms 94.52% of its industry peers.
TGTX's Return On Invested Capital of 6.80% is amongst the best of the industry. TGTX outperforms 94.35% of its industry peers.
Industry RankSector Rank
ROA 4.05%
ROE 10.52%
ROIC 6.8%
ROA(3y)-35.91%
ROA(5y)-48.82%
ROE(3y)-121.2%
ROE(5y)-112.84%
ROIC(3y)N/A
ROIC(5y)N/A
TGTX Yearly ROA, ROE, ROICTGTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

TGTX's Profit Margin of 7.11% is amongst the best of the industry. TGTX outperforms 92.93% of its industry peers.
TGTX has a Operating Margin of 12.74%. This is amongst the best in the industry. TGTX outperforms 94.52% of its industry peers.
With an excellent Gross Margin value of 88.30%, TGTX belongs to the best of the industry, outperforming 89.93% of the companies in the same industry.
TGTX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 12.74%
PM (TTM) 7.11%
GM 88.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.04%
GM growth 5YN/A
TGTX Yearly Profit, Operating, Gross MarginsTGTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), TGTX is destroying value.
The number of shares outstanding for TGTX has been increased compared to 1 year ago.
The number of shares outstanding for TGTX has been increased compared to 5 years ago.
Compared to 1 year ago, TGTX has a worse debt to assets ratio.
TGTX Yearly Shares OutstandingTGTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
TGTX Yearly Total Debt VS Total AssetsTGTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

TGTX has an Altman-Z score of 10.16. This indicates that TGTX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 10.16, TGTX belongs to the top of the industry, outperforming 88.16% of the companies in the same industry.
A Debt/Equity ratio of 1.10 is on the high side and indicates that TGTX has dependencies on debt financing.
The Debt to Equity ratio of TGTX (1.10) is worse than 78.62% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.1
Debt/FCF N/A
Altman-Z 10.16
ROIC/WACC0.68
WACC9.98%
TGTX Yearly LT Debt VS Equity VS FCFTGTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 6.25 indicates that TGTX has no problem at all paying its short term obligations.
TGTX has a Current ratio of 6.25. This is in the better half of the industry: TGTX outperforms 65.37% of its industry peers.
A Quick Ratio of 5.03 indicates that TGTX has no problem at all paying its short term obligations.
With a Quick ratio value of 5.03, TGTX perfoms like the industry average, outperforming 56.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.25
Quick Ratio 5.03
TGTX Yearly Current Assets VS Current LiabilitesTGTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 1300.00% over the past year.
Looking at the last year, TGTX shows a very strong growth in Revenue. The Revenue has grown by 40.80%.
TGTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 364.59% yearly.
EPS 1Y (TTM)1300%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%250%
Revenue 1Y (TTM)40.8%
Revenue growth 3Y266.39%
Revenue growth 5Y364.59%
Sales Q2Q%146.04%

3.2 Future

Based on estimates for the next years, TGTX will show a very strong growth in Earnings Per Share. The EPS will grow by 103.07% on average per year.
TGTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.10% yearly.
EPS Next Y577.57%
EPS Next 2Y276.65%
EPS Next 3Y164.44%
EPS Next 5Y103.07%
Revenue Next Year76.87%
Revenue Next 2Y56.38%
Revenue Next 3Y44.55%
Revenue Next 5Y37.1%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
TGTX Yearly Revenue VS EstimatesTGTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
TGTX Yearly EPS VS EstimatesTGTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 324.07, TGTX can be considered very expensive at the moment.
Based on the Price/Earnings ratio, TGTX is valued cheaper than 91.52% of the companies in the same industry.
TGTX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.88.
Based on the Price/Forward Earnings ratio of 47.83, the valuation of TGTX can be described as expensive.
TGTX's Price/Forward Earnings ratio is rather cheap when compared to the industry. TGTX is cheaper than 92.05% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.20, TGTX is valued quite expensively.
Industry RankSector Rank
PE 324.07
Fwd PE 47.83
TGTX Price Earnings VS Forward Price EarningsTGTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, TGTX is valued cheaper than 91.87% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 165.5
TGTX Per share dataTGTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of TGTX may justify a higher PE ratio.
TGTX's earnings are expected to grow with 164.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.56
PEG (5Y)N/A
EPS Next 2Y276.65%
EPS Next 3Y164.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TGTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TG THERAPEUTICS INC

NASDAQ:TGTX (5/1/2025, 5:02:30 PM)

After market: 45.1 -0.27 (-0.6%)

45.37

-0.14 (-0.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03 2025-03-03/bmo
Earnings (Next)05-06 2025-05-06
Inst Owners63.58%
Inst Owner Change0.14%
Ins Owners10.03%
Ins Owner Change2.96%
Market Cap7.13B
Analysts80
Price Target43.42 (-4.3%)
Short Float %16.64%
Short Ratio8.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)21.82%
Min EPS beat(2)-33.53%
Max EPS beat(2)77.18%
EPS beat(4)2
Avg EPS beat(4)34.31%
Min EPS beat(4)-92.18%
Max EPS beat(4)185.79%
EPS beat(8)5
Avg EPS beat(8)81.62%
EPS beat(12)8
Avg EPS beat(12)57.46%
EPS beat(16)8
Avg EPS beat(16)38.4%
Revenue beat(2)2
Avg Revenue beat(2)3.38%
Min Revenue beat(2)0.65%
Max Revenue beat(2)6.12%
Revenue beat(4)4
Avg Revenue beat(4)7.51%
Min Revenue beat(4)0.65%
Max Revenue beat(4)13.96%
Revenue beat(8)7
Avg Revenue beat(8)50.43%
Revenue beat(12)8
Avg Revenue beat(12)33.46%
Revenue beat(16)10
Avg Revenue beat(16)20.87%
PT rev (1m)5.67%
PT rev (3m)4.47%
EPS NQ rev (1m)0%
EPS NQ rev (3m)40.36%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)6.24%
Revenue NY rev (1m)1.08%
Revenue NY rev (3m)2.8%
Valuation
Industry RankSector Rank
PE 324.07
Fwd PE 47.83
P/S 21.66
P/FCF N/A
P/OCF N/A
P/B 32.05
P/tB 32.05
EV/EBITDA 165.5
EPS(TTM)0.14
EY0.31%
EPS(NY)0.95
Fwd EY2.09%
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS2.09
BVpS1.42
TBVpS1.42
PEG (NY)0.56
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.05%
ROE 10.52%
ROCE 8.61%
ROIC 6.8%
ROICexc 18.82%
ROICexgc 18.82%
OM 12.74%
PM (TTM) 7.11%
GM 88.3%
FCFM N/A
ROA(3y)-35.91%
ROA(5y)-48.82%
ROE(3y)-121.2%
ROE(5y)-112.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.04%
GM growth 5YN/A
F-Score4
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 1.1
Debt/FCF N/A
Debt/EBITDA 5.82
Cap/Depr 66.18%
Cap/Sales 0.01%
Interest Coverage 2.27
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.25
Quick Ratio 5.03
Altman-Z 10.16
F-Score4
WACC9.98%
ROIC/WACC0.68
Cap/Depr(3y)23.6%
Cap/Depr(5y)87.79%
Cap/Sales(3y)0.17%
Cap/Sales(5y)48.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1300%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%250%
EPS Next Y577.57%
EPS Next 2Y276.65%
EPS Next 3Y164.44%
EPS Next 5Y103.07%
Revenue 1Y (TTM)40.8%
Revenue growth 3Y266.39%
Revenue growth 5Y364.59%
Sales Q2Q%146.04%
Revenue Next Year76.87%
Revenue Next 2Y56.38%
Revenue Next 3Y44.55%
Revenue Next 5Y37.1%
EBIT growth 1Y103.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year584.73%
EBIT Next 3Y125.12%
EBIT Next 5YN/A
FCF growth 1Y-29.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.98%
OCF growth 3YN/A
OCF growth 5YN/A